https://www.selleckchem.com/products/gossypol.html
It remains unclear whether people with non-muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor. This is an update of a Cochrane Review first published in 2012. Since that time, several randomized controlled trials (RCTs) have been reported, making this update relevant. OBJECTIVES To assess the comparative effectiveness and toxicity of intravesical gemcitabine instillation for NMIBC. We performed a c
Like
Comment
Share
